Original Research

Pharmaceutical pricing in Croatia: a comparison of ordinances in 2013 versus 2009 and their potential savings to provide future guidance

Published in: Volume 4 / Year 2015 / Issue 2
Author(s): , , , , , ,
Page: 79-89

Introduction: Croatia has introduced a number of reforms to contain pharmaceutical expenditure whilst increasing access to new medicines. These include new regulations and new ordinances in 2013 including the pricing… Read More »

Differences in pharmacokinetic behaviour of branded enoxaparin and a US generic version in a non-human primate model

Published in: Volume 4 / Year 2015 / Issue 2
Author(s): , , , , , , ,
Page: 72-8

Introduction: Low molecular weight heparins (LMWHs) are composed of a heterogeneous mixture of oligosaccharides that express a spectrum of biological activities. Studies conducted in primates (Macaca mulatta) comparing branded and… Read More »

Payer and physician evidence and discount requirements for biosimilars in three Latin American countries

Published in: Volume 4 / Year 2015 / Issue 1
Author(s): , , , ,
Page: 11-6

Study objectives: In Latin America, many governments have attempted to address biosimilar safety and efficacy concerns by developing abbreviated regulatory pathways to increase access while controlling quality. This study explores… Read More »

What pricing and reimbursement policies to use for off-patent biologicals? – Results from the EBE 2014 biological medicines policy survey

Published in: Volume 4 / Year 2015 / Issue 1
Author(s):
Page: 17-24

Objective: One of the questions that the advent of biosimilars raises is whether the different nature of biological medicines would also imply the need for a different policy approach by… Read More »

Availability and procurement conditions of originator and generic medicines in hospitals – an exploratory study in five medium-sized European countries

Published in: Volume 3 / Year 2014 / Issue 4
Author(s): , ,
Page: 168-79

Aim: To explore whether medicines used in hospitals in European countries are supplied as originators or generic medicines, and to investigate the procurement conditions, including the extent of discounts at… Read More »

Ongoing initiatives to improve prescribing efficiency in China; statins as a case history

Published in: Volume 3 / Year 2014 / Issue 3
Author(s): , , , ,
Page: 122-32

Author byline as per print journal: Wenjie Zeng, BSc, PhD; Houmei Xi, B Eng; Brian Godman, BSc, PhD; Alexander E Finlayson, MD, MRCP;  Rickard E Malmstrom, MD, PhD Introduction: Pharmaceutical expenditure… Read More »

Barriers to market uptake of biosimilars in the US

Published in: Volume 3 / Year 2014 / Issue 3
Author(s): , , ,
Page: 108-15

Author byline as per print journal: Joshua P Cohen, PhD; Abigail E Felix, BA; Kim Riggs, MPH; Anumeha Gupta, MD Background: In the US, a new approval pathway for biosimilars has been established… Read More »

GnRH agonists and antagonists in prostate cancer

Published in: Volume 3 / Year 2014 / Issue 3
Author(s): , , ,
Page: 133-42

Author byline as per print journal: Robert Janknegt, PharmD, PhD, Niels Boone, PharmD, Frans Erdkamp, MD, PhD, Victor Zambon, MD Abstract: This manuscript describes the System of Objectified Judgement Analysis… Read More »

Retrospective chart review: disrupted anaemia control in haemodialysis patients following the switch to an iron sucrose similar (ISS) after long-term treatment with the originator iron sucrose (IS)

Published in: Volume 3 / Year 2014 / Issue 3
Author(s): , ,
Page: 116-21

Author byline as per print journal: Professor Jacques Rottembourg, MD; Corinne Emery, MSc; Alessandra Moglia, PhD Study objective: To describe and compare the haematological parameters and the anaemia medication use in… Read More »

Biosimilars naming, label transparency and authority of choice – survey findings among European physicians

Published in: Volume 3 / Year 2014 / Issue 2
Author(s): ,
Page: 58-62

Introduction: A survey of the views of European physicians on familiarity of biosimilar medicines has demonstrated the need for distinguishable non-proprietary names to be given to all biologicals. Methods: The… Read More »

Page 2 of 4 « Previous1 2 3 4 Next »
Go Back Print